Table 3 hTERT-related vaccines
NO | Vaccines | Level | Preclinical Model | Mechanism | Efficacy/Progress |
|---|---|---|---|---|---|
1 | RIAVAX | Clinical | Multiple cells | a. Induce anti-cancer T cells b. Enter into cancer cells and reduce HSP, HIF-1α and VEGF levels c. Inhibit angiogenesis | Help to treat prostate cancer, pancreas cancer, colorectal cancer, and malignant melanoma |
2 | UV1 | Clinical | Multiple cells | Induce TERT-specific T cell and increase T cell activity | In combination with anti-PD1 therapies for the treatment of advanced malignant melanoma |
3 | GRNVAC1 and GRNVAC2 | Clinical | Multiple cells | Expressed TERT in DCs allow them to present TERT-relative antigens | Help to treat Acute Myelogenous Leukemia |
4 | GX301 | Clinical | Multiple cells | Induces TERT-specific T cell immunity | Help treating prostate and renal cancers |
5 | Vx-001 | Clinical | HLA-A*0201 transgenic mouse | Induce and select TERT-specific T cells | Help treating NSCLC and advanced solid tumors |